Noninvasive skin fluorescence spectroscopy for diabetes screening

Journal of Diabetes Science and Technology

Volumn 7, Issue 4, 2013, Pages 1001-1004

  Stirban, Alin ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

Author keywords

Advanced glycation endproducts; Diabetes; Screening; Skin fluorescence spectroscopy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; DIABETES MELLITUS; FLUORESCENCE SPECTROSCOPY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; SCREENING TEST; SKIN FLUORESCENCE SPECTROSCOPY; ANALYSIS; BLOOD; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; MALE; MASS SCREENING; PATHOPHYSIOLOGY; PROCEDURES; SKIN; METHODOLOGY; NOTE;

BLOOD GLUCOSE; FASTING; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MASS SCREENING; SKIN;

EID: 84897124273     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700423     Document Type: Article

References (31)

1. Partnership for Maternal, Newborn, and Child Health; World Health Organization. November 14 is World Diabetes Day! http://www.who.int/pmnch/media/ news/2012/20121114-worlddiabetesday/en/.
2. Peppa M, Uribarri J, Vlassara H. Advanced glycoxidation. A new risk factor for cardiovascular disease? Cardiovasc Toxicol. 2002;2(4):275-87. (Pubitemid 37070568)
3. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2007;9(3):233-45. (Pubitemid 46502041)
4. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care. 2011;34(2):442-7.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20. (Pubitemid 34000785)
6. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002;25(6):1055-9. (Pubitemid 41110493)
7. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315-21.
8. The Diabetes Control and Complications Trial Research Group. The efect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
9. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW; DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010;10(4):276-82.
10. Vlassara H, Bucala R, Striker L: Pathogenic efects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70(2):138-51. (Pubitemid 24090096)
11. Gradinaru D, Borsa C, Ionescu C, Margina D: Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics. 2013. Epub ahead of print.
12. Meerwaldt R, Graaf R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47(7):1324-30. (Pubitemid 39093330)
13. Smit AJ, Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(6):527-33.
14. Na R, Stender IM, Ma L, Wulf HC. Autofluorescence spectrum of skin: component bands and body site variations. Skin Res Technol. 2000;6(3):112-117. (Pubitemid 30459937)
15. Sell DR, Nemet I, Monnier VM: Partial characterization of the molecular nature of collagen-linked fluorescence: role of diabetes and end-stage renal disease. Arch Biochem Biophys. 2010;493(2):192-206.
16. Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ. Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care. 2012;35(11):2331-6.
17. Kessel L, Hougaard JL, Sander B, Kyvik KO, Sorensen TI, Larsen M. Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation - a twin study. Diabetologia. 2002;45(10):1457-62. (Pubitemid 35244901)
18. Olson BP, Matter NI, Ediger MN, Hull EL, Maynard JD. Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance. J Diabetes Sci Technol. 2013;7(4):990-1000.
19. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care. 2007;30(5):1120-4. (Pubitemid 46684635)
20. Tentolouris N, Lathouris P, Lontou S, Tzemos K, Maynard J: Screening for HbA1c-defined prediabetes and diabetes in an at-risk greek population: Performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy. Diabetes Res Clin Pract. 2013;100(1):39-45.
21. Koefoed Theil P, Hansen T, Larsen M, Pedersen O, Lund-Andersen H. Lens autofluorescence is increased in newly diagnosed patients with NIDDM. Diabetologia. 1996;39(12):1524-7. (Pubitemid 26397360)
22. Smit AJ, Smit JM, Botterblom GJ, Mulder DJ. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLOS ONE. 2013. Forthcoming.
23. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39(3):298-305. (Pubitemid 26066801)
24. Stirban A, Pop A, Fischer A, Heckermann S, Tschoepe D. Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment. Diabetes Technol Ther. 2013. To be published.
25. De Ranitz-Greven WL, Kaasenbrood L, Poucki WK, Hamerling J, Bos DC, Visser GH, Biesma DH, Beulens JW, de Valk HW. Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. Diabetes Technol Ther. 2012;14(12):1134-9.
26. Stirban A, Nandrean S, Negrean M, Koschinsky T, Tschoepe D. Skin autofluorescence increases postprandially in human subjects. Diabetes Technol Ther. 2008;10(3):200-5. (Pubitemid 351677591)
27. Noordzij MJ, Lefrandt JD, Graaf R, Smit AJ. Skin autofluorescence and glycemic variability. Diabetes Technol Ther. 2010;12(7):581-5.
28. Lutgers HL, Gerrits EG, Graaf R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52(5):789-97.
29. Meerwaldt R, Links TP, Graaf R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia. 2005;48(8):1637-44. (Pubitemid 41175518)
30. Gerrits EG, Lutgers HL, Kleefstra N, Graaf R, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31(3):517-21.
31. Lutgers HL, Graaf R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2654-9. (Pubitemid 44912194)